EGR2 and myeloid sarcoma: One study reported that there was a lower EGR2 expression in anti-CD3 and anti-CD28 activated CD4+ T cells from human multiple sclerosis (MS) patients when compared to healthy controls, correlating with higher IL-17 production in these cells.